10x Genomics, Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount
10x Genomics, Inc. (TXG) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount of $14.55 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-13.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost · last filed 2026-02-13
- 10x Genomics, Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2025 was $14.55M, a 8.93% decline from fiscal 2024.
- 10x Genomics, Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2024 was $15.98M, a 559.70% increase from fiscal 2023.
- 10x Genomics, Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2023 was $2.42M, a 58.33% decline from fiscal 2022.
- 10x Genomics, Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2022 was $5.81M.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount 12 month |
|---|---|
| 2025-12-31 | $14.55M 10-K · filed 2026-02-13 |
| 2024-12-31 | $15.98M 10-K · filed 2026-02-13 |
| 2023-12-31 | $2.42M 10-K · filed 2026-02-13 |
| 2022-12-31 | $5.81M 10-K · filed 2025-02-13 |
| 2021-12-31 | -$78.85M 10-K · filed 2024-02-15 |
| 2020-12-31 | -$52.07M 10-K · filed 2023-02-16 |
| 2019-12-31 | $1.03M 10-K · filed 2022-02-18 |
| 2018-12-31 | $421.00K 10-K · filed 2020-02-27 |